Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to assess the efficacy of Manremyc® food supplement for reduce the incidence of SARS-CoV-2 infection in a high risk population, as healthcare workers.
Description: % of positive serology at the end of the study or positive PCR test in the course of routine clinical practice
Measure: Documented cumulative incidence of SARS-CoV-2 infection Time: up to 4 monthsDescription: Number of days Documented as sick leave for SARS-CoV-2
Measure: Documented sick leave for SARS-CoV-2 Time: up to 4 months (cumulative)Description: Number of days off work due to the quarantine imposed as a consequence to have acute respiratory symptoms, fever or infection documented by SARS-CoV-2
Measure: days off work due to the quarantine Time: up to 4 monthsDescription: Number of days in quarantine imposed by close contact outside the center with SARS-CoV-2 positive
Measure: Quarantine imposed by close contact outside the center with SARS-CoV-2 positive Time: up to 4 monthsDescription: Number of days of self-reported fever (≥38 ºC)
Measure: Fever Time: Up to 4 monthsDescription: Cumulative incidence of self-reported acute respiratory symptoms
Measure: Cumulative incidence of self-reported acute respiratory symptoms Time: up to 4 monthsDescription: Number of days of self-reported acute respiratory symptoms
Measure: Number of days of self-reported acute respiratory symptoms Time: up to 4 monthsDescription: Number of participants with pneumonia confirmed by X-ray
Measure: Incidence of pneumonia Time: up to 4 monthsDescription: Cumulative incidence of death from documented SARS-CoV-2 infection
Measure: Cumulative incidence of death from documented SARS-CoV-2 infection Time: Up to 4 monthsDescription: Cumulative incidence of admissions to intensive care unit for documented SARS-CoV-2 infection
Measure: Incidence of admission to ICU Time: Up to 4 monthsDescription: Number of days admitted to the ICU for documented SARS-CoV-2 infection
Measure: Days in IUC Time: Up to 4 monthsDescription: Cumulative incidence of need for mechanical ventilation due to documented SARS-CoV-2 infection
Measure: Incidence of mechanical ventilation Time: Up to 4 monthsDescription: Cumulative incidence of hospital admissions for documented SARS-CoV-2 infection
Measure: Incidence of hospital admissions Time: Up to 4 monthsDescription: Number of days of hospitalization for documented SARS-CoV-2 infection
Measure: Days of hospitalization Time: Up to 4 monthsDescription: Levels of IgG
Measure: Levels of IgG Time: Up to 4 monthsDescription: Levels of IgM
Measure: Levels of IgM Time: Up to 4 monthsDescription: Levels of SARS-CoV-2 antibodies at the end of the study period
Measure: Levels of SARS-CoV-2 antibodies at the end of the study period Time: Up to 4 monthsDescription: All adverse events reported by the subjects, both serious and non-serious, will be collected. All events related to a SARS-CoV-2 infection will be exempted from collection, as they will be collected as part of the associated symptoms
Measure: AEs Time: Up to 4 monthsDescription: All thoseAdverse Events that lead to hospitalization of the patient, that endanger his life or cause or may cause death.
Measure: SAEs Time: Up to 4 mothsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports